Hims & Hers Health surges 40% pre-market; Novo Nordisk partners with Hims to sell weight-loss drug Wegovy at reduced prices

Hims & Hers Health surges 40% pre-market; Novo Nordisk partners with Hims to sell weight-loss drug Wegovy at reduced prices

Hims & Hers Health, Inc. (HIMS) experienced a significant pre-market surge, climbing 40% on April 29, 2025, following an announcement of a strategic partnership with Novo Nordisk. The telehealth and wellness company has agreed to sell Novo Nordisk's weight-loss drug Wegovy at reduced prices, marking a significant milestone for both companies.

The pre-market rally for HIMS shares was driven by the strategic partnership, which aims to make the weight-loss drug more accessible to a broader audience. Wegovy, a once-weekly injectable medication, has been highly sought after due to its effectiveness in managing obesity. By partnering with Hims & Hers Health, Novo Nordisk seeks to leverage the latter's extensive telehealth and wellness platform to reach more customers.

This strategic move comes at a time when Hims & Hers Health is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. Analysts anticipate quarterly earnings of $0.14 per share, representing a year-over-year change of +180%, with revenues expected to be $537.85 million, up 93.4% from the year-ago quarter [1].

The partnership with Novo Nordisk is likely to bolster HIMS's revenue streams and customer base, potentially contributing to its earnings growth. Additionally, the company's recent earnings estimate revisions and Earnings ESP suggest that analysts are becoming increasingly bullish on the company's prospects [1].

Despite the pre-market surge, HIMS shares have been volatile in recent months, trading below its 52-week high of $72.98. The stock's price movements have been influenced by various factors, including market sentiment, macroeconomic trends, and the company's ongoing expansion into new health and wellness sectors [2].

As Hims & Hers Health continues to expand its service offerings and strategic partnerships, investors should keep an eye on its earnings report scheduled for May 5, 2025, to assess the company's financial performance and the impact of the Novo Nordisk partnership.

References:
[1] https://www.nasdaq.com/articles/hims-hers-health-inc-hims-earnings-expected-grow-should-you-buy-1
[2] https://www.apnakal.com/market/hims-hers-health-inc-hims-sees-market-volatility-stock-reverses-gains-trading-below-52-week-high/